| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2003;75:430-437
© 2003 The Society of Thoracic Surgeons
a Department of Anesthesiology, Munich, Germany
b Department of Clinical Chemistry, Munich, Germany
c Department of Cardiac Surgery, German Heart Center, Munich, Germany
d Institute for Clinical Biochemistry, Ludwig-Maximilians-University, Munich, Germany
Accepted for publication September 5, 2002.
* Address reprint requests to Dr Mössinger, German Heart Center, Lazarettstr 36, 80636 Munich, Germany
e-mail: moessinger{at}dhm.mhn.de
BACKGROUND: Though multiple studies have affirmed the effectiveness of aprotinin in reducing blood loss in adult cardiac surgery, the possible benefit in pediatric cardiac surgery is controversial.
METHODS: In a double-blind, randomized, and placebo-controlled study, the efficacy of aprotinin in attenuating the hemostatic and inflammatory activation during cardiopulmonary bypass in 60 patients weighing less than 10 kg was investigated. Secondary endpoints were the influence of aprotinin on the reduction of blood loss and allogeneic blood requirement, as well as postoperative oxygenation and length of mechanical ventilation. Aprotinin was administered in a high-dose of 3 x 104 KIU/kg plus a bolus of 5 x 105 KIU (not weight adjusted) added to the pump prime.
RESULTS: Aprotinin plasma concentration at the end of cardiopulmonary bypass (CPB) was with 184 ± 45 KIU/mL, within the targeted range of 200 KIU/mL. Coagulation and fibrinolysis were suppressed (F1.2 1 hour after CPB: 5.35 ± 2.9 nmol/L vs 14.5 ± 23.1 nmol/L; D-dimer 1 hour after CPB: 0.63 ± 0.6 ng/mL vs 2.3 ± 3.1 ng/mL; p < 0.05), inflammatory markers (interleukin [IL]-6, IL-8, IL-10) increased over time without significant differences between the groups, and only complement C3a activation was significantly attenuated at the end of CPB in the aprotinin group. Chest tube drainage was significantly reduced (24 hours: median 13.5 [IQR 12.2] mL/kg vs 19.4 [8.2] mL/kg; p < 0.05). All patients received one unit of packed cells to prime the heart lung machine. A second unit was needed significantly less often in the aprotinin group (13% vs 47%; p < 0.05). Postoperative oxygenation (pO2/FIO2 172 [IQR 128] mm Hg vs 127 [74]; p < 0.05) improved, and the time on ventilator was shorter in the aprotinin group (median 45 hours [IQR 94] vs 101 [IQR 74]; p < 0.05). No side effects were attributable to the use of aprotinin.
CONCLUSIONS: High-dose aprotinin effectively attenuated hemostatic activation and reduced blood loss and transfusion requirement in pediatric cardiac surgery. Postoperative ventilation was also shortened in the aprotinin group.
This article has been cited by other articles:
|
|
 |
|
  M. P. Eaton Antifibrinolytic Therapy in Surgery for Congenital Heart Disease Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Dietrich, A. Ebell, R. Busley, and A.-L. Boulesteix Aprotinin and Anaphylaxis: Analysis of 12,403 Exposures to Aprotinin in Cardiac Surgery Ann. Thorac. Surg., October 1, 2007; 84(4): 1144 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. McEvoy, S. T. Reeves, J. G. Reves, and F. G. Spinale Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of Action Anesth. Analg., October 1, 2007; 105(4): 949 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Mossad, S. Machado, and J. Apostolakis Bleeding following deep hypothermia and circulatory arrest in children. Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2007; 11(1): 34 - 46. [Abstract] [PDF]
|
|
|
|
|
|
W. Dietrich, R. Busley, and M. Kriner High-Dose Aprotinin in Cardiac Surgery: Is High-Dose High Enough?: An Analysis of 8281 Cardiac Surgical Patients Treated with Aprotinin Anesth. Analg., November 1, 2006; 103(5): 1074 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Guzzetta, B. E. Miller, K. Todd, F. Szlam, R. H. Moore, K. K. Brosius, E. C. Wilson, A. M. Cohen, and S. R. Tosone Clinical Measures of Heparin's Effect and Thrombin Inhibitor Levels in Pediatric Patients with Congenital Heart Disease Anesth. Analg., November 1, 2006; 103(5): 1131 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sedrakyan, A. Wu, G. Sedrakyan, M. Diener-West, M. Tranquilli, and J. Elefteriades Aprotinin use in thoracic aortic surgery: Safety and outcomes J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 909 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Guay, P. de Moerloose, and D. Lasne Minimizing perioperative blood loss and transfusions in children: [Reduire les pertes sanguines et les besoins transfusionnels en chirurgie pediatrique]. Can J Anesth, June 1, 2006; 53(6_suppl): S59 - S67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Arnold, D. A. Fergusson, A. K.C. Chan, R. J. Cook, G. A. Fraser, W. Lim, M. A. Blajchman, and D. J. Cook Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin. Anesth. Analg., March 1, 2006; 102(3): 731 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Schultz, T. Karamlou, J. Swanson, I. Shen, and R. M. Ungerleider Hypothermic Low-Flow Cardiopulmonary Bypass Impairs Pulmonary and Right Ventricular Function More Than Circulatory Arrest Ann. Thorac. Surg., February 1, 2006; 81(2): 474 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Fischer and M. Steinhoff Effects of aprotinin on endothelium-dependent relaxation of large coronary arteries Eur. J. Cardiothorac. Surg., December 1, 2005; 28(6): 801 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G Raja and G. D Dreyfus Modulation of Systemic Inflammatory Response after Cardiac Surgery Asian Cardiovasc Thorac Ann, December 1, 2005; 13(4): 382 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Huebler, W. Boettcher, A. Koster, M. Emeis, P. Lange, and R. Hetzer Transfusion-Free Complex Cardiac Surgery With Cardiopulmonary Bypass in a 3.55-Kg Jehovah's Witness Neonate Ann. Thorac. Surg., October 1, 2005; 80(4): 1504 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Williams, R. J. Ing, J. P. Hart, J. Jaggers, F. H. Kern, D. M. Craig, and S. V. Pizzo Soluble {alpha}2-macroglobulin receptor is increased in endotracheal aspirates from infants and children after cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1098 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Guzzetta, B. E. Miller, K. Todd, F. Szlam, R. H. Moore, and S. R. Tosone An Evaluation of the Effects of a Standard Heparin Dose on Thrombin Inhibition During Cardiopulmonary Bypass in Neonates Anesth. Analg., May 1, 2005; 100(5): 1276 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bombeli and D. R. Spahn Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage Br. J. Anaesth., August 1, 2004; 93(2): 275 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Jones The year in cardiovascular surgery J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1706 - 1714. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
